Skip to main content
NCBI home page
Heart logoLink to Heart
. 1997 Nov;78(5):444–449. doi: 10.1136/hrt.78.5.444

β Blockade in congestive heart failure: persistent adverse haemodynamic effects during chronic treatment with subsequent doses

M Kukin 1, J Kalman 1, M Mannino 1, C Buchholz-Varley 1, O Ocampo 1
PMCID: PMC1892308  PMID: 9415001

Abstract

Objective—To determine whether the acute adverse haemodynamic effects of β blockade in patients with congestive heart failure persist during chronic treatment.
Design—Sequential haemodynamic evaluation of heart failure patients at baseline and after three months of continuous treatment with the β1 selective antagonist metoprolol.
Setting—Cardiac care unit in university hospital.
Patients—26 patients with moderate to severe congestive heart failure (New York Heart Association grade II to IV) and background treatment with digoxin, diuretics, and angiotensin converting enzyme inhibitors, and with a left ventricular ejection fraction < 25%.
Methods—Baseline variables included a six minute walk, maximum oxygen consumption, and right heart catheterisation. All patients received metoprolol 6.25 mg orally twice daily initially and the dose was gradually increased to a target of 50 mg twice daily. Haemodynamic measurements were repeated after three months of treatment, both before (trough) and after drug readministration.
Results—Long term metoprolol had functional, exercise, and haemodynamic benefits. It produced decreases in heart rate, pulmonary capillary wedge pressure, and systemic vascular resistance, and increases in cardiac index, stroke volume index, and stroke work index. However, when full dose metoprolol was readministered during chronic treatment, there was a reduction in cardiac index (from 2.8 (SD 0.46) to 2.3 (0.38) l/min/m2, p << 0.001) and stroke work index (from 31.4 (11.1) to 26.6 (10.0) g.m/m2, p < 0.001) and an increase in systemic vascular resistance (from 943 (192) to 1160 (219) dyn.s.cm−5, p << 0.001).
Conclusions—Adverse haemodynamic effects of β blockers in heart failure persist during chronic treatment, as shown by worsening haemodynamic indices with subsequent doses.

 Keywords: heart failure;  β blockers;  adverse effects

Full Text

The Full Text of this article is available as a PDF (157.1 KB).

Figure 1  .

Figure 1  

Open in a new tab

Haemodynamic indices of (A) pulmonary capillary wedge pressure, (B) cardiac index, (C) systemic vascular resistance, and (D) stroke work index at baseline (B), long term trough after three months of metoprolol treatment (LT-B), and two hours after drug readministration (LT-P). Error bars are SEM. P values are designated to show differences from B to LT-B and from LT-B to LT-P for the 22 completers.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson B., Blomström-Lundqvist C., Hedner T., Waagstein F. Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure. J Am Coll Cardiol. 1991 Oct;18(4):1059–1066. doi: 10.1016/0735-1097(91)90767-4. [DOI] [PubMed] [Google Scholar]
  2. Bristow M. R., Ginsburg R., Minobe W., Cubicciotti R. S., Sageman W. S., Lurie K., Billingham M. E., Harrison D. C., Stinson E. B. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982 Jul 22;307(4):205–211. doi: 10.1056/NEJM198207223070401. [DOI] [PubMed] [Google Scholar]
  3. Bristow M. R. The adrenergic nervous system in heart failure. N Engl J Med. 1984 Sep 27;311(13):850–851. doi: 10.1056/NEJM198409273111310. [DOI] [PubMed] [Google Scholar]
  4. Engelmeier R. S., O'Connell J. B., Walsh R., Rad N., Scanlon P. J., Gunnar R. M. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation. 1985 Sep;72(3):536–546. doi: 10.1161/01.cir.72.3.536. [DOI] [PubMed] [Google Scholar]
  5. Fowler M. B., Laser J. A., Hopkins G. L., Minobe W., Bristow M. R. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation. 1986 Dec;74(6):1290–1302. doi: 10.1161/01.cir.74.6.1290. [DOI] [PubMed] [Google Scholar]
  6. Gilbert E. M., Abraham W. T., Olsen S., Hattler B., White M., Mealy P., Larrabee P., Bristow M. R. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996 Dec 1;94(11):2817–2825. doi: 10.1161/01.cir.94.11.2817. [DOI] [PubMed] [Google Scholar]
  7. Gilbert E. M., Anderson J. L., Deitchman D., Yanowitz F. G., O'Connell J. B., Renlund D. G., Bartholomew M., Mealey P. C., Larrabee P., Bristow M. R. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med. 1990 Mar;88(3):223–229. doi: 10.1016/0002-9343(90)90146-5. [DOI] [PubMed] [Google Scholar]
  8. Guyatt G. H., Sullivan M. J., Thompson P. J., Fallen E. L., Pugsley S. O., Taylor D. W., Berman L. B. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985 Apr 15;132(8):919–923. [PMC free article] [PubMed] [Google Scholar]
  9. Heilbrunn S. M., Shah P., Bristow M. R., Valantine H. A., Ginsburg R., Fowler M. B. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989 Mar;79(3):483–490. doi: 10.1161/01.cir.79.3.483. [DOI] [PubMed] [Google Scholar]
  10. Kim S. G. The management of patients with life-threatening ventricular tachyarrhythmias: programmed stimulation or Holter monitoring (either or both)? Circulation. 1987 Jul;76(1):1–5. doi: 10.1161/01.cir.76.1.1. [DOI] [PubMed] [Google Scholar]
  11. Krum H., Sackner-Bernstein J. D., Goldsmith R. L., Kukin M. L., Schwartz B., Penn J., Medina N., Yushak M., Horn E., Katz S. D. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995 Sep 15;92(6):1499–1506. doi: 10.1161/01.cir.92.6.1499. [DOI] [PubMed] [Google Scholar]
  12. Metra M., Nardi M., Giubbini R., Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994 Dec;24(7):1678–1687. doi: 10.1016/0735-1097(94)90174-0. [DOI] [PubMed] [Google Scholar]
  13. Miller R. R., Olson H. G., Amsterdam E. A., Mason D. T. Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. N Engl J Med. 1975 Aug 28;293(9):416–418. doi: 10.1056/NEJM197508282930902. [DOI] [PubMed] [Google Scholar]
  14. Olsen S. L., Gilbert E. M., Renlund D. G., Taylor D. O., Yanowitz F. D., Bristow M. R. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995 May;25(6):1225–1231. doi: 10.1016/0735-1097(95)00012-S. [DOI] [PubMed] [Google Scholar]
  15. Packer M., Bristow M. R., Cohn J. N., Colucci W. S., Fowler M. B., Gilbert E. M., Shusterman N. H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23;334(21):1349–1355. doi: 10.1056/NEJM199605233342101. [DOI] [PubMed] [Google Scholar]
  16. Packer M., Medina N., Yushak M. Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure. Circulation. 1985 Apr;71(4):761–766. doi: 10.1161/01.cir.71.4.761. [DOI] [PubMed] [Google Scholar]
  17. Swedberg K., Hjalmarson A., Waagstein F., Wallentin I. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J. 1980 Aug;44(2):134–142. doi: 10.1136/hrt.44.2.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Swedberg K., Hjalmarson A., Waagstein F., Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J. 1980 Aug;44(2):117–133. doi: 10.1136/hrt.44.2.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Swedberg K., Hjalmarson A., Waagstein F., Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet. 1979 Jun 30;1(8131):1374–1376. doi: 10.1016/s0140-6736(79)92010-5. [DOI] [PubMed] [Google Scholar]
  20. Waagstein F., Bristow M. R., Swedberg K., Camerini F., Fowler M. B., Silver M. A., Gilbert E. M., Johnson M. R., Goss F. G., Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993 Dec 11;342(8885):1441–1446. doi: 10.1016/0140-6736(93)92930-r. [DOI] [PubMed] [Google Scholar]
  21. Waagstein F., Caidahl K., Wallentin I., Bergh C. H., Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 1989 Sep;80(3):551–563. doi: 10.1161/01.cir.80.3.551. [DOI] [PubMed] [Google Scholar]
  22. Waagstein F., Hjalmarson A., Varnauskas E., Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975 Oct;37(10):1022–1036. doi: 10.1136/hrt.37.10.1022. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES